Yi Lin, MD, PhD


Dr Lin on Findings From the CARTITUDE-1 Trial in Relapsed/Refractory Multiple Myeloma

Yi Lin, MD, PhD, discusses findings from the primary analysis of the phase 1/2 CARTITUDE-1 trial of the BCMA-targeting CAR T-cell therapy ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Mount Sinai


A Mount Sinai-Led Study Shows Early Success of a Novel Drug in Treating a Rare and Chronic Blood Cancer

In a trial led by the Icahn School of Medicine at Mount Sinai, rusfertide demonstrated the ability to control the overproduction of RBCs in polycythemia vera.

Yazan Madanat, MD


Final Thoughts on Recent Data Updates in MDS

Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.

Jason Henry, MD


Recent Updates in Early Onset Colorectal Cancer: What We Know and Where to Go

Oncologists globally explore trends, challenges in diagnosis, and future directions in patients with colorectal cancer.

Jose Maria Mazarico Gallego, MD


Dr. Gallego on the Impact of COVID-19 on Cancer Care in Spain

Jose Maria Mazarico Gallego, MD, discusses the impact of the COVID-19 pandemic on cancer care in Spain.

Neil Vasan, MD, PhD


Dr. Vasan on Advancing the Treatment of Small HER2+ Breast Cancer

Neil Vasan, MD, discusses advances made in the treatment of patients with small HER2-positive breast cancer.

Michelina Cairo, MD


Dr Cairo on the Safety Profiles of T-DM1 vs T-DXd in HER2+ Metastatic Breast Cancer

Michelina Cairo, MD, discusses the adverse effect profiles of trastuzumab emtansine and trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.

Sabina Signoretti, MD


Dr Signoretti on the Development of Novel Biomarkers in RCC Using Tissue-Based Analyses

Sabina Signoretti, MD, discusses research into the development of novel spatial biomarkers in renal cell carcinoma utilizing tissue-based in situ analyses.

Ignace B. Vergote, MD, PhD


Dr Vergote on the Efficacy of Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

Ignace B. Vergote, MD, PhD, discusses the efficacy of tisotumab vedotin-tftv in patients with recurrent or metastatic cervical cancer, according to data from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628).

Erin Roesch, MD


A Dynamic Treatment Landscape Emerges for Early-Stage TNBC

Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.

John Nakayama, MD


FDA Approvals of Immunotherapy in Gynecology Oncology

In this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.

Alison Schram, MD


Dr. Schram on the Efficacy of RLY-4008 in FGFR2+ Cholangiocarcinoma

Alison Schram, MD, discusses the efficacy and safety of RLY-4008 in patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Patrick Boland, MD


Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC

Patrick Boland, MD, discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer.

Janeesh Sekkath Veedu, MBBS


Dr Sekkath Veedu on Survival Outcomes With Surgery vs Chemoradiation in Stage IIIA NSCLC

Janeesh Sekkath Veedu, MBBS, discusses the survival advantage conferred by surgical-based treatment compared with definitive chemoradiation in patients with stage IIIA non–small cell lung cancer.

Upal Basu Roy, PhD, MPH


Dr. Basu Roy on the Challenges of Interpreting Molecular Testing Results in Lung Cancer

Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.

Thomas Cluzeau, MD, PhD


Summary of Unmet Needs and Future Directions in MDS

Experts close by summarizing key advances and remaining unmet needs across all MDS risk groups, and share their hopes for the future.

Anne P. O’Dea, MD


Optimizing Management of HR+/HER2- BC: Future Directions in Care

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.

Allen Mo, MD, PhD


28-Gene Score May Predict Distant Metastatic Recurrence in Advanced Head and Neck Cancers

Although the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.

Henry S. Park, MD, MPH


Dr Park on the Role of Radiation Therapy in NSCLC

Henry S. Park, MD, MPH, discusses the importance of considering radiation therapy in patients with non–small cell lung cancer and how this therapeutic approach can work in concert with targeted therapy and other systemic therapies.

Doris M. Ponce, MD


Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and Hobbs

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Adam Kittai, MD


Dr Kittai on an Indirect Comparison of Acalabrutinib Plus Obinutuzumab vs Zanubrutinib in CLL/SLL

Adam Kittai, MD, discusses key findings from a matching-adjusted, indirect comparison of acalabrutinib with or without obinutuzumab vs zanubrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.

George Lau, MD, FRCP, FAASLD


Dr Lau on the Temportal Patterns of irAEs Associated With the Stride Regimen in HCC

George Lau, MD, FRCP, FAASLD, discusses clinical implications for the use of dual checkpoint inhibition in HCC based on an analysis of immune-related adverse effects seen with the STRIDE regimen in the phase 3 HIMALAYA trial.

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center


Dr. Brufsky on the Efficacy of Enobosarm in ER+/AR+ Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.

David O’Malley, MD


Interpreting Results From RAMP 201: Avutometinib +/- Defactinib in Recurrent LGSOC

Expert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape.

Leo Rasche, MD


Dr Rasche on BCMA and GPRC5D Loss After Bispecific Antibody Therapy in Multiple Myeloma

Leo Rasche, MD, discusses BCMA and GPRC5D loss after bispecific antibody therapy in multiple myeloma.

Byoung Chul Cho, MD, PhD


Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC

Byoung Chol Cho, MD, PhD, discusses findings from the CHRYSALIS-2 trial of amivantamab plus lazertinib in patients with atypical EGFR-mutant NSCLC.

Muthu Veeraputhiran, MD


The Evolving Treatment Landscape in Paroxysmal Nocturnal Hemoglobinuria

The treatment landscape for PNH is rapidly evolving, and clinicians have more effective and convenient treatment options for patients that have helped control the disease and improve survival. T

Larry Hanover


Clinical Trial Diversity Efforts Gain Steam

Nearly 30 years after National Institutes of Health sought to increase participation of minorities in clinical trials, a demographic imbalance remains.